0000950170-24-075568.txt : 20240620
0000950170-24-075568.hdr.sgml : 20240620
20240620160506
ACCESSION NUMBER: 0000950170-24-075568
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240611
FILED AS OF DATE: 20240620
DATE AS OF CHANGE: 20240620
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Buell Jennifer
CENTRAL INDEX KEY: 0001711184
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-29089
FILM NUMBER: 241056175
BUSINESS ADDRESS:
BUSINESS PHONE: 781-674-4400
MAIL ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AGENUS INC
CENTRAL INDEX KEY: 0001098972
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 061562417
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-674-4410
MAIL ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIGENICS INC /DE/
DATE OF NAME CHANGE: 19991115
3
1
ownership.xml
3
X0206
3
2024-06-11
0
0001098972
AGENUS INC
AGEN
0001711184
Buell Jennifer
3 FORBES ROAD
LEXINGTON
MA
02421
true
true
false
false
Chairman Executive Council
Common Stock
13670
D
Stock Option, right to buy
100.80
2015-05-12
2025-02-12
Common Stock
1225
D
Stock Option, right to buy
100.80
2015-02-12
2025-02-12
Common Stock
525
D
Stock Option, right to buy
83.2
2017-03-31
2026-03-31
Common Stock
5000
D
Stock Option, right to buy
75.40
2018-03-31
2027-03-31
Common Stock
6250
D
Stock Option, right to buy
41.40
2018-11-07
2028-11-07
Common Stock
6500
D
Stock Option, right to buy
47.60
2019-06-19
2029-06-19
Common Stock
15000
D
Stock Option, right to buy
82.40
2019-12-24
2029-12-24
Common Stock
24999
D
Stock Option, right to buy
72.20
2020-06-15
2030-06-15
Common Stock
500
D
Stock Option, right to buy
74.00
2020-12-17
2030-12-17
Common Stock
44999
D
Stock Option, right to buy
63.60
2021-06-16
2031-01-01
Common Stock
45000
D
Stock Option, right to buy
64.40
2022-01-02
2032-01-02
Common Stock
7500
D
Stock Option, right to buy
47.40
2023-01-09
2033-01-09
Common Stock
37500
D
Stock Option, right to buy
11.80
2024-06-11
2034-01-17
Common Stock
37500
D
Options awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan (as amended) and vests over four years with one third vesting on the 2-year anniversary of the grant date (January 1, 2021) and the balance in equal quarterly installments thereafter.
Options awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan (as amended) and vests over three years with one third vesting on the one year anniversary of the grant date (January 1, 2022) and the balance in equal quarterly installments thereafter.
Options awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan (as amended) and vests over three years with one third vesting on the one year anniversary of the grant date (January 9, 2023) and the balance in equal quarterly installments thereafter.
Options were granted on January 17, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on January 16, 2025 and the balance vesting in equal quarterly installments thereafter. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 750,000 Stock Options with an exercise price of $0.59..
Christine M. Klaskin, by Power of Attorney
2024-06-18